Upon closing of the purchase, United Therapeutics will receive $350 million in profit exchange for the PPRV. The voucher was awarded by the FDA under a provision that encourages advancement of new drugs and biologics for the prevention and treatment of uncommon pediatric diseases. We are very very happy to monetize our PPRV, and hope that transaction shall motivate others to become listed on us in focusing advancement efforts on rare pediatric diseases, stated Roger Jeffs, Ph.D., United Therapeutics' President and Co-CEO. The transaction is at the mercy of customary closing clearance and conditions beneath the Hart-Scott-Rodino Antitrust Improvements Act..A growing number of women, including nonsmokers, are diagnosed with lung cancer every year, said Phyllis Greenberger, president and CEO of the Society for Women’s Health Research. We have to improve women’s awareness of this disease and we are in need of more research to understand the effect of sex and gender on the advancement and treatment of lung tumor. The federal government can play a significant role in this technique by increasing funding for analysis and education targeted at the underserved human population of women. Lung cancers statements the lives of even more American people compared to the three most common cancers mixed – – colon, breast, and prostate – – however it gets a disproportionately low amount of media attention and government analysis funding.